Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Topolcan

Showing results (111-120 of 120) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 120 results.
Bratislavske Lekarske Listy|March 8, 2012
Matrix metalloproteinases and their inhibitors in correlation to proliferative and classical tumour markers during surgical therapy of colorectal liver metastasesV Liska, A Sutnar, L Holubec, et al.
Anticancer Research|October 15, 2010
Importance of miR-20a expression in prostate cancer tissueM Pesta, J Klecka, V Kulda, et al.
Anticancer Research|July 26, 2007
Tumor markers in pleural effusionsO Topolcan, L Holubec, V Polivkova, et al.
European Journal of Cancer (Oxford, England : 1990)|May 22, 2007
Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical useM J Duffy, A van Dalen, C Haglund, et al.
Anticancer Research|May 1, 2001
The significance of CEA, CA19-9 and CA72-4 in the detection of colorectal carcinoma recurrenceL Holubec, O Topolcan, R Pikner, et al.
Anticancer Research|August 17, 2005
Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samplesM Pesta, L Holubec, O Topolcan, et al.
Anticancer Research|March 25, 2010
Differential display code 3 (DD3/PCA3) in prostate cancer diagnosisJ Klecka, L Holubec, M Pesta, et al.
Anticancer Research|July 23, 2005
Clinical relevance of tumor markers for the control of chemotherapyJ Finek, L Holubec, O Topolcan, et al.
Anticancer Research|July 22, 2005
Markers of cellular adhesion in diagnosis and therapy control of colorectal carcinomaL Holubec, O Topolcan, J Finek, et al.
Neoplasma|May 10, 2017
Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexedO Fiala, P Hosek, M Pesek, et al.
Pageof 12

Showing results (111-120 of 120) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 120 results.
Bratislavske Lekarske Listy|March 8, 2012
Matrix metalloproteinases and their inhibitors in correlation to proliferative and classical tumour markers during surgical therapy of colorectal liver metastasesV Liska, A Sutnar, L Holubec, et al.
Anticancer Research|October 15, 2010
Importance of miR-20a expression in prostate cancer tissueM Pesta, J Klecka, V Kulda, et al.
Anticancer Research|July 26, 2007
Tumor markers in pleural effusionsO Topolcan, L Holubec, V Polivkova, et al.
European Journal of Cancer (Oxford, England : 1990)|May 22, 2007
Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical useM J Duffy, A van Dalen, C Haglund, et al.
Anticancer Research|May 1, 2001
The significance of CEA, CA19-9 and CA72-4 in the detection of colorectal carcinoma recurrenceL Holubec, O Topolcan, R Pikner, et al.
Anticancer Research|August 17, 2005
Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samplesM Pesta, L Holubec, O Topolcan, et al.
Anticancer Research|March 25, 2010
Differential display code 3 (DD3/PCA3) in prostate cancer diagnosisJ Klecka, L Holubec, M Pesta, et al.
Anticancer Research|July 23, 2005
Clinical relevance of tumor markers for the control of chemotherapyJ Finek, L Holubec, O Topolcan, et al.
Anticancer Research|July 22, 2005
Markers of cellular adhesion in diagnosis and therapy control of colorectal carcinomaL Holubec, O Topolcan, J Finek, et al.
Neoplasma|May 10, 2017
Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexedO Fiala, P Hosek, M Pesek, et al.
Pageof 12